FDA approves Roche’s HPV self-collection screening option

Betsy Goodfellow | May 15, 2024 | News story | Medical Communications FDA, HPV, Oncology, Roche, cervical cancer 

Roche has announced that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-collection solution. This makes the solution one of the first available in the US, allowing more women to utilise an accessible screening option.

This testing option requires women to collect their own vaginal samples in a healthcare setting, which is then sent to a laboratory for analysis.

Roche has undertaken collaborations with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on its Cervical Cancer “Last Mile” initiative, which has contributed to the regulatory approval of this novel screening option.

Advertisement

Currently, more than 50% of patients in the US who are diagnosed with cervical cancer have never been screened or have only had infrequent screening and do not participate in routine screening, therefore innovations making screening more accessible are a step in the right direction.

Matt Sause, chief executive officer of Roche Diagnostics, commented: “With vaccinations, innovative diagnostic tools and screening programmes, achieving the World Health Organization’s (WHO) goal of eliminating cervical cancer by 2030 is within reach. Our HPV self-collection solution helps support this goal by reducing barriers and providing access to HPV screening by allowing people to privately collect their own sample for HPV testing.”

Betsy Goodfellow

Related Content

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance …

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …

Outrun Therapeutics announces its lead programme for HPV positive cancer

Outrun Therapeutics has selected an E6AP inhibitor strategy as its lead programme for treating HPV …

The Gateway to Local Adoption Series

Latest content